Bio­gen be­gins lay­ing off staff as it con­tin­ues to push its new Alzheimer's drug

The lay­offs at Bio­gen have be­gun.

In the wake of a con­tro­ver­sial ap­proval for its Alzheimer’s drug Aduhelm, Bio­gen start­ed in­form­ing em­ploy­ees Wednes­day that their roles were be­ing elim­i­nat­ed, the big biotech said in a state­ment, as part of a cost-cut­ting plan im­ple­ment­ed in De­cem­ber. Bio­gen is giv­ing no de­tails on the ex­act num­ber of lay­offs, a prac­tice that falls out­side the stan­dard pro­ce­dure of pub­licly trad­ed com­pa­nies even though they are not legal­ly re­quired to do so.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.